Introduction: Plasma cell gingivitis (PCG) is an unusual inflammatory condition characterized by dense, band-like polyclonal plasmacytic infiltration of the lamina propria. Clinically, it appears as gingival enlargement with erythema and swelling of the attached and free gingiva and is not associated with any loss of attachment. The aim of this report is to present a rare case of severe generalized aggressive periodontitis (GAgP) associated with a PCG lesion that was successfully treated and maintained non-surgically.

Case Presentation: A 32-year-old white male with a non-contributory medical history presented with gingival enlargement with diffuse erythema and edematous swelling, predominantly around teeth #5 through #8. Clinical and radiographic examination revealed generalized severe periodontal breakdown. A complete blood count and biochemical tests were within normal limits. Histologic and immunohistochemical examination were consistent with PCG. A diagnosis of severe GAgP associated with a PCG lesion was assigned. Treatment included elimination of possible allergens and non-surgical periodontal treatment in combination with azithromycin. Clinical examination at reevaluation revealed complete resolution of gingival enlargement, erythema, and edema and localized residual probing depths of 5 mm. One year after treatment, the clinical condition was stable. Radiographs indicated improved bone levels and formation of crestal lamina dura.

Conclusion: This case report highlights the unusual coexistence of GAgP and PCG, in which non-surgical treatment with elimination of all possible causes in combination with antimicrobials resulted in elimination of the gingival enlargement and significant improvement of periodontal parameters.

Download full-text PDF

Source
http://dx.doi.org/10.1902/cap.2013.130050DOI Listing

Publication Analysis

Top Keywords

gingival enlargement
16
generalized aggressive
8
aggressive periodontitis
8
plasma cell
8
cell gingivitis
8
case report
8
non-surgical treatment
8
enlargement erythema
8
gagp associated
8
associated pcg
8

Similar Publications

Gingival Debulking Surgery for a Child With Severe Aplastic Anemia: A Case Report.

Spec Care Dentist

January 2025

Paediatric Dentistry, The University of Western Australia, Dental School, Perth, Australia.

Introduction: Aplastic anemia (AA) is a rare condition that frequently manifests with pancytopenia. Management of severe disease is through either allogenic stem cell transplantation or immunosuppressive therapy with supportive care. Drug-induced gingival overgrowth (DIGO) is a potential complication of a number of medications, including cyclosporine and amlodipine.

View Article and Find Full Text PDF

Background: Complicated crown-root fracture (CRF) involves severe injury to the crown, root, and pulp, and may be accompanied by multiple root fractures. The loss of a tooth has lifelong consequences for children and teenagers, but the maintenance of pulp health and the calcific healing of multiple root fractures are rarely reported in the literature.

Case Summary: This case reports healing of a permanent tooth with complicated crown-root and additional root fractures, in which pulp health was maintained.

View Article and Find Full Text PDF

Marked Gingival Overgrowth Protruding from the Oral Cavity Due to Sodium Valproate.

Diagnostics (Basel)

January 2025

Department of Pediatrics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi 260-8670, Chiba, Japan.

Drug-induced gingival overgrowth is associated with various systemic diseases, including epilepsy. Among antiepileptic medications, phenytoin is commonly reported to cause this condition. In contrast, sodium valproate (VPA), another widely used antiepileptic drug, rarely induces gingival overgrowth.

View Article and Find Full Text PDF

Gingival enlargements are mostly plaque-induced. Other than plaque, a few genetic conditions also cause enlargements of the gingiva. In recent years, there has been a notable rise in drug-induced gingival overgrowth (DIGO) linked to the increased use of medications for various systemic conditions.

View Article and Find Full Text PDF

: Although BRAF inhibitors, such as vemurafenib, produce a marked response in patients with advanced melanoma with a BRAF V600 mutation, they eventually develop resistance to this treatment. To address this issue, vemurafenib is increasingly combined with the MEK inhibitor cobimetinib, leading to improved response rates and enhanced survival. However, this treatment modality is associated with numerous side effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!